Ottawa Hospital Rehabilitation Centre.
Respir Care. 2013 Oct;58(10):1598-605. doi: 10.4187/respcare.02275. Epub 2013 Apr 2.
The purpose of this study was to compare the ability of 3 portable oxygen concentrators (POCs) to maintain S(pO2) ≥ 90% during exercise in patients with chronic lung disease.
Twenty-one subjects with chronic lung disease (18 with COPD, 3 with pulmonary fibrosis) and documented room air exertional S(pO2) ≤ 85% performed four 6-min walk tests: a control walk using the subject's current oxygen system and prescribed exertional flow rate, and 1 walk with each of the 3 POCs (Eclipse 3, EverGo, and iGo) at their maximum pulse-dose setting.
S(pO2) was significantly higher pre-walk and post-walk with the Eclipse 3, compared to the other POCs (all P < .01). The subjects also walked farther and maintained a mean S(pO2) ≥ 90% with the Eclipse 3 (both P < .01), which delivers the largest oxygen bolus. The subjects indicated that they preferred the EverGo's physical characteristics, but that the Eclipse 3 responded best to their breathing. The iGo was rated less favorably than Eclipse 3 or EverGo.
The Eclipse 3 was best at meeting the subjects' clinical needs. POC users should be appropriately tested during all activities of daily living, to ensure adequate oxygenation. The healthcare provider should provide information and help to direct the subject toward the most clinically appropriate oxygen system, while being mindful of the patient's preferences and lifestyle. (Clinicaltrials.gov NCT01653730).
本研究旨在比较 3 种便携式氧气浓缩器(POC)在慢性肺病患者运动时维持 S(pO2)≥90%的能力。
21 名慢性肺病(18 名 COPD,3 名肺纤维化)患者和记录的空气运动 S(pO2)≤85%的患者进行了 4 次 6 分钟步行测试:使用患者当前氧气系统和规定运动流量的对照步行,以及 3 种 POC(Eclipse 3、EverGo 和 iGo)的 1 次步行,均在其最大脉冲剂量设置下。
与其他 POC 相比,Eclipse 3 在预步行和步行后 S(pO2)显著升高(均 P<0.01)。与其他 POC 相比,Eclipse 3 还使患者行走距离更远,并保持平均 S(pO2)≥90%(均 P<0.01),因为它提供了最大的氧气脉冲量。患者表示他们更喜欢 EverGo 的物理特性,但 Eclipse 3 对他们的呼吸反应最好。iGo 的评价不如 Eclipse 3 或 EverGo。
Eclipse 3 最能满足患者的临床需求。POC 用户应在所有日常生活活动中进行适当的测试,以确保充足的氧合。医疗保健提供者应提供信息并帮助指导患者选择最适合临床的氧气系统,同时注意患者的偏好和生活方式。(Clinicaltrials.gov NCT01653730)。